116 related articles for article (PubMed ID: 27687081)
1. Falsely elevated serum oestradiol due to exemestane therapy.
Mandic S; Kratzsch J; Mandic D; Debeljak Z; Lukic I; Horvat V; Gaudl A; Seric V
Ann Clin Biochem; 2017 May; 54(3):402-405. PubMed ID: 27687081
[TBL] [Abstract][Full Text] [Related]
2. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
3. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography tandem mass spectrometry determination of free and conjugated estrogens in breast cancer patients before and after exemestane treatment.
Zhao Y; Boyd JM; Sawyer MB; Li XF
Anal Chim Acta; 2014 Jan; 806():172-9. PubMed ID: 24331053
[TBL] [Abstract][Full Text] [Related]
5. Exemestane: an alternative treatment option in early breast cancer. Foreward.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S1. PubMed ID: 18340241
[No Abstract] [Full Text] [Related]
6. The evolving role of exemestane in the management of breast cancer.
Bundred N
Br J Hosp Med (Lond); 2006 Aug; 67(8):427-30. PubMed ID: 16918105
[TBL] [Abstract][Full Text] [Related]
7. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
Zilembo N; Noberasco C; Bajetta E; Martinetti A; Mariani L; Orefice S; Buzzoni R; Di Bartolomeo M; Di Leo A; Laffranchi A
Br J Cancer; 1995 Oct; 72(4):1007-12. PubMed ID: 7547212
[TBL] [Abstract][Full Text] [Related]
8. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
[No Abstract] [Full Text] [Related]
9. Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
Samuel E; Chiang C; Jennens R; Faulkner D; Francis PA
Eur J Cancer; 2020 Feb; 126():104-105. PubMed ID: 31927211
[No Abstract] [Full Text] [Related]
10. Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma.
Ksycińska H; Buś-Kwaśnik K; Szlagowska A; Rudzki PJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1905-10. PubMed ID: 21641878
[TBL] [Abstract][Full Text] [Related]
11. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
[TBL] [Abstract][Full Text] [Related]
13. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
Goss PE; Richardson H; Chlebowski R; Johnston D; Sarto GE; Maunsell E; Ingle JN; Alés-Martinez JE
Clin Breast Cancer; 2007 Dec; 7(11):895-900. PubMed ID: 18269782
[No Abstract] [Full Text] [Related]
14. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Mareck U; Geyer H; Guddat S; Haenelt N; Koch A; Kohler M; Opfermann G; Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2006; 20(12):1954-62. PubMed ID: 16715475
[TBL] [Abstract][Full Text] [Related]
15. Exemestane: a novel aromatase inactivator for breast cancer.
Jones SA; Jones SE
Clin Breast Cancer; 2000 Oct; 1(3):211-6. PubMed ID: 11899645
[TBL] [Abstract][Full Text] [Related]
16. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Takagi K; Miki Y; Nagasaki S; Hirakawa H; Onodera Y; Akahira J; Ishida T; Watanabe M; Kimijima I; Hayashi S; Sasano H; Suzuki T
Endocr Relat Cancer; 2010 Jun; 17(2):415-30. PubMed ID: 20228125
[TBL] [Abstract][Full Text] [Related]
17. The role of aromatase inactivators in the treatment of breast cancer.
Lønning PE
Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
[TBL] [Abstract][Full Text] [Related]
18. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
19. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Crucitta E; Fornier MN; Locopo N; Silvestris N; Lorusso V; De Lena M
Int J Oncol; 2002 Jun; 20(6):1283-8. PubMed ID: 12012011
[TBL] [Abstract][Full Text] [Related]
20. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
